XML 88 R64.htm IDEA: XBRL DOCUMENT v3.22.4
Principal Accounting Policies - Additional Information (Details)
£ in Thousands, $ in Millions
1 Months Ended 12 Months Ended
Aug. 31, 2022
GBP (£)
Aug. 31, 2022
USD ($)
Dec. 31, 2022
GBP (£)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
GBP (£)
Segment
Dec. 31, 2021
USD ($)
Segment
Dec. 31, 2020
GBP (£)
Dec. 31, 2019
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Significant Accounting Policies [Line Items]                      
Loss for the year after taxation | £     £ 40,489   £ 39,410   £ 32,547        
Accumulated losses | £     263,263   222,966            
Upfront payments received | £     72,349   £ 76,748   £ 68,379        
Cash and cash equivalents and U.S. Treasury Bills     £ 71,100           $ 86.0    
Aggregate gross proceeds from underwritten offering £ 46,400 $ 56.5                  
Underwriting discounts, commissions and estimated offering expenses £ 3,300 $ 4.1                  
Number of reportable segment | Segment         1 1          
Percentage of revenue increased     0.40% 0.40%              
Percentage of estimated costs increased     10.00% 10.00%              
Performance Obligations With Hansoh                      
Significant Accounting Policies [Line Items]                      
Upfront payments received                   $ 16.0  
Standalone selling price per target       $ 16.0              
Upfront payments                 4.0    
Global target on benchmarking exercise       8.0              
Performance Obligations With Mallinckrodt                      
Significant Accounting Policies [Line Items]                      
Upfront payments received               $ 20.0      
Standalone selling price per target               $ 20.0      
Performance Obligations With AstraZeneca                      
Significant Accounting Policies [Line Items]                      
Upfront payments received                   60.0 $ 60.0
Standalone selling price per target       $ 60.0              
Top of Range                      
Significant Accounting Policies [Line Items]                      
Milestones to be received in next 12 months                 $ 14.0    
Intangible assets with indefinite useful life     15 years 15 years              
Top of Range | Licences and Software                      
Significant Accounting Policies [Line Items]                      
Intangible assets with indefinite useful life     15 years 15 years              
Top of Range | Equipment and Furniture                      
Significant Accounting Policies [Line Items]                      
Estimated useful economic life of property, plant and equipment     10 years 10 years              
Bottom of Range                      
Significant Accounting Policies [Line Items]                      
Intangible assets with indefinite useful life     10 years 10 years              
Percentage of share capital of another entity     90.00% 90.00%              
Bottom of Range | Licences and Software                      
Significant Accounting Policies [Line Items]                      
Intangible assets with indefinite useful life         10 years 10 years          
Bottom of Range | Equipment and Furniture                      
Significant Accounting Policies [Line Items]                      
Estimated useful economic life of property, plant and equipment     3 years 3 years              
AstraZeneca collaboration                      
Significant Accounting Policies [Line Items]                      
Upfront payments received         £ 30,800         40.0  
Hansoh collaboration                      
Significant Accounting Policies [Line Items]                      
Upfront payments received         10,700         $ 16.0  
American Depositary Shares | Major Ordinary Share Transactions                      
Significant Accounting Policies [Line Items]                      
Proceeds from private placement           $ 45.0          
Proceeds from private placement, net of expenses         £ 30,800 $ 42.0